Drug intelligence / Profile preview

AT-006

Development stage: Unknown
Lead developer: Aratana Therapeutics
Administration: Topical

Overview

AT-006 is a veterinary drug initially developed by Aratana Therapeutics for two distinct indications. For canine osteoarthritis, it is marketed under the brand name Galliprant, with exclusive global rights for its development, manufacturing, and commercialization granted to Elanco Animal Health. Additionally, AT-006 is being developed as a topical antiviral treatment for feline ocular herpes, a program that was enhanced through Aratana's acquisition of Okapi Sciences.

Brand names: Galliprant

Beyond the preview

Go deeper on AT-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-006.

Explore the full profile